Beta
50261

Anti-Mullerian Hormone as A new Marker for Diagnosis of Poly Cystic Ovary Syndrome

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

-

Abstract

Background: Polycystic ovary syndrome (PCOS) is a complex disease characterized by various endocrine disorders that are the potential cause of anovulation and hyperandrogenism. This heterogeneous syndrome affects about 5– 10% of reproductive-age female population and it can be considered the most common endocrine disorder affecting women during reproductive life. PCOS is a multifactorial polygenic disease. Genes that regulate steroidogenesis and folliculogenesis are interested. Hence, AMH measurement has been found to offer a relatively high specificity and sensitivity as a diagnostic marker. Objectives: The study aimed to assess the accuracy of AMH in the prediction of PCOS in patients admitted to Elsayed Galal and El Hussein University Hospital. Subjects and methods: This was a retrospective study that was done on 130 women, divided into two groups, group I include 100 PCOS patients and group II, 30 control subject. Results: The results of this study showed that there was no significant difference between the two groups regarding age, while there was a significant increase in BMI in patients more than in control. The level of LH showed a significant increase in patients more than in the control. The level of FSH showed a significant decrease in patients less than in the control. The Testosterone showed a significant increase in patients more than in the control. The androstenedione showed a significant increase in patients more than in the control group. The AMH showed a highly significant increase in patients more than in the control and in turn the number of follicles in group II (patients) was significantly higher than in the control. The sensitivity of AMH in diagnosis PCOS was 98.0, specificity was 80.0% and the total accuracy was 93.0 at the cutoff of point 0.911. Conclusion: Additional advantages of AMH as diagnostic tool are that it is biological, objective, quantitative marker not affected by day of menses or OCP intake. So in future, more studies should be undertaken to validate its role as diagnostic tool for PCOS.

DOI

10.21608/ejhm.2019.50261

Keywords

Anti Mullerian Hormone, Diagnosis, Poly Cystic Syndrome

Authors

First Name

Abdel Monieum Mohamed

Last Name

Zakaria

MiddleName

-

Affiliation

Department of Obstetrics and Gynecology, Faculty of Medicine Al-Azhar University

Email

-

City

-

Orcid

-

First Name

Ahmed

Last Name

Osama

MiddleName

-

Affiliation

Department of Obstetrics and Gynecology, Faculty of Medicine Al-Azhar University

Email

-

City

-

Orcid

-

First Name

Ahmed Kamal Mohamed

Last Name

Abo Sheashea

MiddleName

-

Affiliation

Department of Obstetrics and Gynecology, Faculty of Medicine Al-Azhar University

Email

-

City

-

Orcid

-

Volume

77

Article Issue

3

Related Issue

7685

Issue Date

2019-10-01

Receive Date

2019-09-28

Publish Date

2019-10-01

Page Start

5,096

Page End

5,100

Print ISSN

1687-2002

Online ISSN

2090-7125

Link

https://ejhm.journals.ekb.eg/article_50261.html

Detail API

https://ejhm.journals.ekb.eg/service?article_code=50261

Order

3

Type

Original Article

Type Code

606

Publication Type

Journal

Publication Title

The Egyptian Journal of Hospital Medicine

Publication Link

https://ejhm.journals.ekb.eg/

MainTitle

Anti-Mullerian Hormone as A new Marker for Diagnosis of Poly Cystic Ovary Syndrome

Details

Type

Article

Created At

22 Jan 2023